Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether combination treatment of Teclistamab and
Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the
onset of multiple myeloma.